Tafamidis is a transthyretin (TTR) stabiliser used for transthyretin amyloid cardiomyopathy (ATTR-CM), a serious heart condition in which misfolded protein builds up in the heart muscle and makes it stiff over time. It is one of the few medicines that act on the underlying cause rather than only the symptoms.

• Approved indication: Cardiomyopathy caused by wild-type or hereditary transthyretin amyloidosis (ATTR-CM) in adults, to reduce cardiovascular death and hospitalisation
• Drug class: Transthyretin stabiliser
• How it works: Binds to the transthyretin protein and keeps it stable, which slows the breakdown that leads to amyloid deposits
• Usual dosing: One 61 mg capsule once a day, as prescribed
• Time to benefit: Benefit builds gradually, usually over 6 to 18 months, so treatment is long-term
• Evidence: In the pivotal ATTR-ACT trial, tafamidis significantly reduced all-cause mortality and heart-related hospitalisations versus placebo
• Why it matters for buyers: Treatment is ongoing, so a dependable and affordable supply route is as important as the first order

• Do not use in: Patients allergic to tafamidis or any ingredient
• Not interchangeable by milligram: Different tafamidis formulations (the free acid and the meglumine salt) are not swapped milligram for milligram, so the prescribed form and strength should always be matched
• Swallow whole: Capsules should not be crushed or cut
• Pregnancy and breastfeeding: Animal studies showed risk to the developing baby, so use in pregnancy is not recommended. Breastfeeding is not advised during treatment
• Interactions: Tafamidis may raise levels of certain medicines cleared by the BCRP transporter (such as methotrexate or rosuvastatin), so the doctor should review the full medicine list
• Thyroid tests: Total thyroxine levels may fall without clinical hypothyroidism, which the doctor should keep in mind when reading results
• Side effects: Generally well tolerated. Diarrhoea has been reported
• Monitoring: No routine lab monitoring is required for the medicine itself, but regular cardiology follow-up continues
• Switching products: Any change between originator and generic should be made by the treating physician

Availability: Current stock, strength, and pricing are confirmed once you share your quantity and destination country. A verified quote is typically shared within 24 hours.

• Logistics: Standard export logistics by air or sea, with no cold chain required, which keeps freight cost low
• Active corridors: The GCC and Middle East, Southeast Asia, Africa, and Latin America
• Tracking: Full shipment tracking, with customs documentation support
• Order size: Flexible quantities for hospitals, distributors, and access programmes

What is Tafamidis used for?

It treats transthyretin amyloid cardiomyopathy (ATTR-CM), helping reduce heart-related death and hospital stays in adults.

How do I get a Tafamidis price quote from a GMP-compliant Indian supplier?

Please share your required strength, quantity, and destination country. We will respond with a verified quote, usually within 24 hours.

Is Tafamidis available from India for export?

Yes, tafamidis 61 mg capsules are available through India’s manufacturing network, and we supply hospitals and distributors worldwide.

Is Tafamidis available in every country?

Availability depends on the molecule’s patent and registration position in each country. We check this before quoting.

Does Tafamidis need cold chain shipping?

No. It is a room-temperature stable capsule and ships through standard export logistics.